Clinical trial
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
NCT00003156 · Gynecologic Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00003156 |
|---|---|
| Title | Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus |
| Official title | Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Start date | Jun 1, 1998 |
| Primary completion | Oct 1, 2005 |
| First posted | Apr 7, 2004 |
| Last update posted | Apr 11, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: